Corey N. Fishman insider trades: Iterum Therapeutics (ITRM) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Corey reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 20, 2023 | ITRM | ↑ Buy | 10,000 | $1.59 | $16K | Direct | Nov 20, 2023 (0d) |
| Jan 26, 2021 | ITRM | ↓ Sell | 85,445 | $1.73 | $148K | Direct | Jan 27, 2021 (1d) |
| Aug 17, 2018 | ITRM | ↑ Buy | 2,000 | $8.73 | $17K | Direct | Aug 21, 2018 (4d) |
| May 30, 2018 | ITRM | ↑ Buy | 3,000 | $13.00 | $39K | Direct | May 30, 2018 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ITRM insiders
Open-market trades in the last 12 months
About Corey N. Fishman's insider trades
Corey N. Fishman is Chief Executive Officer at Iterum Therapeutics (ITRM). Since May 30, 2018, Corey has reported 3 open-market purchases worth $72K and 1 sale worth $148K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (15 filings), option exercises (5 filings), shares returned to the company (2 filings), conversions (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ITRM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.